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http://dx.doi.org/10.1016/j.ccr.2014.01.010SUMMARYThe Hippo pathway has been implicated in suppressing tissue overgrowth and tumor formation by restricting
the oncogenic activity of YAP. However, transcriptional regulators that inhibit YAP activity have not been well
studied. Here, we uncover clinical importance for VGLL4 in gastric cancer suppression and find that VGLL4
directly competes with YAP for binding TEADs. Importantly, VGLL4’s tandem Tondu domains are not only
essential but also sufficient for its inhibitory activity toward YAP. A peptide mimicking this function of
VGLL4 potently suppressed tumor growth in vitro and in vivo. These findings suggest that disruption of
YAP-TEADs interaction by a VGLL4-mimicking peptide may be a promising therapeutic strategy against
YAP-driven human cancers.INTRODUCTION
Hippo pathway controls organ size in diverse species from
Drosophila to human. This pathway features a central kinase
cascade formed by Hippo (Hpo; MST1/2 in mammals) andWarts
(Wts; LATS1/2 in mammals) (Huang et al., 2005), whose activa-
tions lead to phosphorylation of the downstream transcriptional
coactivator Yorkie (Yki; YAP/TAZ in mammals), thus preventing
its interaction with and therefore transactivation of the DNA-
binding transcriptional factor Scalloped (Sd; TEADs/TEF in
mammals) (Goulev et al., 2008; Wu et al., 2008; Zhang et al.,
2008; Zhao et al., 2008). Inactivation of the Hippo signaling leads
to proproliferation and anti-apoptosis associated with increased
cancer risk (Halder and Johnson, 2011; Harvey and Tapon, 2007;
Pan, 2010; Zeng and Hong, 2008; Zhao et al., 2010).
As a downstream effector, YAP plays a key role in Hippo
pathway to control cell proliferation. Despite a possible suppres-
sor function in some circumstances (Barry et al., 2013), YAP wasSignificance
As an emerging significant player in tumorigenesis, the Hippo
ment of new anticancer drugs. In contrast to targeting upstream
ultimate downstreameffector of Hippo signaling, may provide a
Our findings that VGLL4 is a natural antagonist of YAP, and it
development of a peptide-based YAP inhibitor. This peptide po
tunity for treating gastric cancer that currently lacks effectiv
extended to other cancer types driven by hyperactive YAP.
166 Cancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc.mostly reported as an oncoprotein and its elevated expression
and nuclear localization have been frequently observed in human
cancers (i.e., lung cancers, liver cancers, colon cancers, pancre-
atic cancer, and breast cancers) (Avruch et al., 2012; Cui et al.,
2012; Hergovich, 2012; Pan, 2010; Steinhardt et al., 2008;
Zender et al., 2006; Zhang et al., 2011; Zhao et al., 2007). The
role of YAP as a promising and important therapeutic target
has been increasingly recognized. However, research regarding
specific YAP inhibitors and their potential therapeutic use in
treating cancers remains very limited with only a few reports so
far confined to small-molecule inhibitors (Liu-Chittenden et al.,
2012).
As a transcriptional coactivator, YAP does not contain any
DNA-binding domain but functions through interaction with
TEADs, whereby inducing expression of target genes promoting
cell proliferation as well as inhibiting apoptosis. Similar to YAP,
the mammalian Vestigial-like proteins VGLL1-4 do not contain
DNA-binding domain and they also exert their transcriptionalpathway has attracted increasing attention for the develop-
regulators such asMST1/2 and LATS, inhibition of YAP, the
more effective and direct way to redress theHippo pathway.
s TDU region is sufficient for YAP inhibition, allowed for the
tently suppresses gastric tumor growth, providing an oppor-
e treatment options. The therapeutic strategy may also be
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VGLL4: An Anticancer Drug Candidate Targeting YAPregulatory functions through pairing with TEADs via their Tondu
(TDU) domain(s). Specifically, VGLL1-3 proteins share one con-
served TDU domain at their N-terminal regions, while VGLL4
has two partially conserved TDU domains at its C terminus
(Chen et al., 2004; Maeda et al., 2002; Pobbati et al., 2012; Vau-
din et al., 1999). Most studies to date have identified VGLL1-3 as
TEADs-related transcriptional coactivators (Faucheux et al.,
2010; Gu¨nther et al., 2004; Halperin et al., 2013; Maeda et al.,
2002). The function of VGLL4 has not been clearly defined, how-
ever, although it has been suggested as a candidate tumor sup-
pressor in pancreatic adenocarcinoma (Mann et al., 2012).
Recently, we and others have identified VGLL4 in Drosophila
and human as a transcriptional repressor that inhibits YAP-
induced overgrowth and tumorigenesis (Guo et al., 2013; Koontz
et al., 2013; Zhang et al., 2014). However, the possible role of
VGLL4 in human gastric cancer (GC) has not been defined, and
the potential therapeutic application of VGLL4 remains unknown.
Human GC is characteristic of poor prognosis and high death
rate, making it the second most common cause of cancer-
related death worldwide. Therefore, there is a great need to iden-
tify new prognostic markers as well as develop novel therapeutic
strategies in GC treatment. In this work, we set out to investigate
the clinical relevance of VGLL4 and its regulatory function and
mechanism in Hippo pathway, aiming to discover and design a
peptide drug candidate against gastric cancer.
RESULTS
VGLL4 Is a Potential Tumor Suppressor in Human
Gastric Cancer
To explore a potential role of VGLL4 in gastric tumorigenesis, we
first examined its mRNA levels in 84 human gastric tumor clinical
specimens. Univariate analysis indicated that themRNA levels of
VGLL4 were downregulated in 51 out of 84 (61%) GC samples
(p < 0.0087) (Figure 1A). We collected and preprocessed
patients’ data by extracting nine available clinical factors in three
categories, i.e., the clinical background (age, gender), immuno-
histochemistry data (Lauren’s classification, tumor differentia-
tion, lymphatic invasion), and the cancer’s stage information
(tumor size, lymph node metastasis, distant metastasis, tumor
stage) (Table 1). Considering the important role of Helicobacter
pylori infection in gastric tumorigenesis, we also included
H. pylori infectious status for patient analysis. These data indi-
cated that aberrant levels of VGLL4mRNA were inversely corre-
lated not only with tumor size and tumor stage, but also with
lymphatic invasion and lymph node metastasis. Downregulation
of VGLL4 was found in 5 of 14 grade I (35.7%), 10 of 19 grade II
(52.6%), 16 of 26 grade III (61.5%), and 20 of 25 grade IV (80%)
(p = 0.044) GC samples. Consistent with our observations at
mRNA level, VGLL4 expression at protein level also showed an
inverse correlation with GC progression (Figure 1B and Fig-
ure S1A available online). Semiquantitative immunoblot analysis
undertaken for 24 pairs of gastric tumor samples showed that
protein levels of VGLL4 in grades I and II were much higher
than those in grades III and IV (p = 0.026). To further determine
the potential association of VGLL4 expression with clinical out-
comes, we performed immunohistochemical (IHC) staining of
VGLL4 on tissue microarrays containing 91 GC specimens that
have a long-term clinical follow-up record (four lost to follow-Cup). VGLL4 staining was significantly associated with tumor
size, lymph node metastasis, and TNM stage (p < 0.05), but
not significantly correlated to age, gender, and tumor metabasis
(Table S1). The positive rates of VGLL4 in both dysplasia
(abnormal growth of gastric mucosa) and GC samples were
significantly lower than that in normal tissues (p < 0.05) (Fig-
ure 1C). Subsequent Kaplan-Meier survival analysis showed
that expression levels of VGLL4 were inversely correlated with
5 year survival rate of GC patients (p = 0.0416) (Figure 1D).
Together, these results suggested that VGLL4 is a potential
tumor suppressor as well as an independent prognostic marker
for overall survival of GC patients (relative risk: 0.2110, 95% con-
fidence interval [CI]: 0.1932–0.6315, p = 0.0215) (Table S2).
Previously, it has been reported that increased YAP mRNA
levels in GC samples are correlated with lymphatic metastasis
and tumor TNM stage (Zhou et al., 2013). In our study, we found
that YAPmRNA levels were not only associated with tumor size,
differentiation, and stage, but also withH. pylori infectious status
(p < 0.05) (Table S3). YAP-positive rates in GC and dysplasia
were much higher than that in normal tissues (p < 0.01) (Fig-
ure S1B). Consistently, the protein levels of YAP also tend to in-
crease in higher tumor grade (Figure S1A). Notably, we found
that the average ratio of YAP to VGLL4 at mRNA levels in higher
grade tumor samples is significantly higher than in lower grade
tumor samples (p < 0.05) (Table S4). Moreover, the YAP/
VGLL4 ratio at mRNA level is strongly correlated with GC clinical
factors including lymphatic invasion, tumor size, TNM stage, and
H. pylori infectious status (Table S5). Consistently, the average
ratio of YAP to VGLL4 at protein levels increases from 2.7 ±
0.4 in tumor tissues of stage I to 9.1 ± 1.6 in GC samples of stage
IV (Table S3). IHC analysis showed that among YAP-positive GC
patients, those with VGLL4-positive expression have a better
clinical outcome (survival time: 39 months) when compared
with VGLL4 negative expression (survival time: 16 months) (Fig-
ure 1D). Taken together, these results indicate that YAP/VGLL4
ratio could be considered as an important clinical factor for GC
classification and diagnosis.
Overexpression of YAP target genesCTGF,CYR61, andCDX2
have been suggested to correlate with GC progression (Da et al.,
2009; Jacobson and Cunningham, 2012; Jiang et al., 2011; Kang
et al., 2011; Lin et al., 2005; Maeta et al., 2007; Zhao et al., 2011;
Zhou et al., 2013). Consistent with these reports, we observed an
elevated expression of YAP (Figure S1C) and its target genes
CTGF and CYR61 in GC tissues than those in paired control tis-
sues (Figure 1E). In our experiment, upregulation of CDX2 was
not statistically significant, despite of their increasing tendency
(Figure 1E). Importantly, we found that downregulation of
VGLL4 mRNA was correlated with upregulation of YAP target
genes CTGF, CYR61, and CDX2 (Figure 1F). Moreover, hierar-
chical cluster analysis showed that during the early stage of
GC (stage I and II), mRNA levels of YAP target genes CTGF
andCYR61 in high VGLL4 expression groupwas obviously lower
than those in normal and low VGLL4 expression group (Fig-
ure S1D). Further tumor stage analysis found that VGLL4 expres-
sion in high tumor stage was lower than that in low tumor stage,
while the expressions of CTGF and YAP were significantly upre-
gulated along tumor progression (Figure S1E). Patients with
higher YAP/VGLL4 ratio also have higher expressions of YAP
target genes CTGF, CYR61, and CDX2 (Figure S1F). Together,ancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc. 167
Figure 1. Downregulation of VGLL4 Was Associated with Upregulation of YAP Target Genes and GC Prognosis
(A) VGLL4mRNA levels in GC. mRNA levels of VGLL4 in 84 paired human GC and normal tissues were examined by real-time PCR, using GAPDH as an internal
control. Bar value (DCt(N)-DCt(T)) represents the difference of VGLL4mRNA levels between normal tissue and tumor. Bar value > 1 indicates that VGLL4mRNA
(legend continued on next page)
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VGLL4: An Anticancer Drug Candidate Targeting YAPthese results indicated that VGLL4 may affect YAP-TEADs tran-
scriptional activity in GC.
VGLL4 Suppresses GC Growth in Vitro by Targeting
YAP-TEADs
To confirm a biological role of VGLL4 in GC, we first checked the
effect of VGLL4 on the growth of several GC cell lines with
different differentiation states including BGC-823, HGC-27,
MGC-803, and MKN-45. First, we analyzed the expression pro-
files of YAP and VGLL4, as well as YAP/VGLL4 protein ratio in
these cells (Figure S2A). Except MKN-45, all other three GC
cell lines appear to have increased YAP levels and decreased
VGLL4 levels. As a result, the YAP/VGLL4 ratios are much higher
in BGC-823, HGC-27, and MGC-803 cells than those in MKN-
45 and HEK293 cells. Next, we found that overexpression
of VGLL4 in MGC-803 cells (YAP/VGLL4 ratio: 3.6) not only
induced apoptosis, but also inhibited cell viability on plate and
anchorage-independent cell growth in soft agar (Figures 2A–
2C). To examine whether VGLL4’s function is related to a poten-
tial inhibition against YAP-TEADs transcriptional activity, we
performed TEAD4 reporter assay and analyzed downstream
target genes’ expression. As shown in Figures 2D and 2E, both
TEAD4 reporter activity and expressions of YAP-TEADs target
genesCTGF,CYR61, andCDX2were reduced upon transfection
of VGLL4 in MGC-803 cells. Similar results were observed for
BGC-823 (YAP/VGLL4 ratio: 2.2) and HGC-27 (YAP/VGLL4 ratio:
4.0) cells (Figures S2B–S2F). By contrast, overexpression of
VGLL4 in MKN-45 cells (YAP/VGLL4 ratio: 0.1) did not signifi-
cantly promote apoptosis or inhibit cell growth and colony for-
mation (Figures S2B–S2D). Meanwhile, TEAD4 reporter activity
and the target genes’ expression were not significantly altered
either in MKN-45 cells (Figures S2E and S2F).
Next, we depleted endogenous VGLL4 by special short hairpin
RNA (shRNA) targeting its 50-UTR. Our results showed that
knockdown of VGLL4 in BGC-823, MGC-803, and HGC-27 pro-
moted cell growth and enhanced both TEAD4 reporter activity
and target genes’ expression (Figures 2F–2H and S2G–S2I).
Such effects could be rescued by transfection of VGLL4 back
into these cells (Figures 2G and S2H). By contrast, the viability,
TEAD4 trans-activity, and downstream target genes’ expression
were not significantly altered by knockdown of VGLL4 in MKN-
45 cells (Figures S2G–S2I). Taken together, these results indi-
cated that VGLL4 inhibits GC growth in vitro in a way related to
cellular YAP/VGLL4 ratio, and importantly, VGLL4 functions
through targeting YAP-TEADs transcriptional activity.
To assess the functional importance of the potential TEADs-
binding domain of VGLL4, namely the tandem TDU domains,level is increased in tumors. Bar value <1 indicates that VGLL4mRNA level is de
of normal group and cancer group.
(B) VGLL4 protein levels at different tumor grades of GC. VGLL4 expression i
immunoblotting with specific antibodies and plotted as indicated. The horizonta
formed to compare the variation between stage I and other tumor stages. *Versu
(C) Representative cores of VGLL4 staining on tissue microarray.
(D) Kaplan-Meier survival curves of overall patients (left) and YAP-positive patients
rank test.
(E) Relative mRNA levels of YAP target genes CTGF (left), CYR61 (middle), and C
(F) Scatter plot between VGLL4 and YAP target genes in GC. Relative mRNA leve
(middle), and CDX2 (right) by Spearman’s correlation.
See also Figure S1 and Tables S1–S5.
Cwe generated several deletion mutants of VGLL4 (Figure 2I).
Our results showed that deletion of the tandem TDU domains
of VGLL4 totally abrogated its inhibitory effect on cell growth
(Figure 2J). Moreover, deletion of the first TDU domain (TDU1)
only moderately impaired VGLL4’s inhibition of cell growth,
while deletion of the second TDU domain (TDU2) almost com-
pletely abolished such function. Consistently, clonogenic assays
showed that introduction of wild-type VGLL4, but not the TDU-
deletion mutants inhibited clonogenicity of MGC-803 cells in a
dose-dependent manner at both basal and YAP-induced levels
(Figure 2K). Meanwhile, deletion of VGLL4 TDU1, TDU2 or the
whole tandem TDU region impaired or abolished its inhibitory
activity toward YAP-induced TEAD4 reporter activity (Figure 2L).
Moreover, VGLL4 TDU deletion mutants failed to inhibit YAP-
induced CDX2 expression (Figure 2M). Taken together, these
results indicated that the tandem TDU region, especially TDU2,
is functionally essential for VGLL4.
Structural Study Identified Key Residues for
VGLL4-TEAD4 Complex Formation
Given the importance of the tandem TDU domains for VGLL4
function, we performed a structural study of the VGLL4-TEAD4
complex. As shown by gel filtration and dynamic light scattering
assays, the tandem TDU region of VGLL4 directly interacts with
the YAP-binding domain (YBD) of TEAD4 and form a stable com-
plex with a molar ratio of 1:2 (Figures S3A and S3B). We then
determined the crystal structure of mouse VGLL4 tandem TDU
region in complex with the YBD domain of mouse TEAD4 (Table
S6). Consistent with our solution studies, each TDU domain of
VGLL4 binds one molecule of TEAD4 (Figures 3A, S3C, and
S3D). TDU1 is composed of only one a helix (helix a1), while
TDU2 consists of a b strand followed by two short a helices
(helices a2 and a3) packed against each other (Figures 3A–3C).
Due to its highly extended conformation of the tandem TDUs,
the two bound TEAD4 molecules (assigned as A and B) do not
contact with each other. Thus, TDU1 and TDU2 appear to func-
tion as individual binding units for separate TEADs molecules.
Next, we investigated the details of the VGLL4-TEAD4 com-
plex interface, which is dominated by hydrophobic interactions.
Residues V206, H209, F210, R212, and L214 of TDU1 form a hy-
drophobic core with F330, Y362, F366, K369, L370, L373, M378,
and V382 of the TEAD4 molecule A (Figure 3B). A total surface
area of 588 A˚2 is buried upon TDU1 binding with TEAD4. On
the other hand, residues V235, H237, F238, K240, and L242 of
TDU2 form a hydrophobic core with TEAD4 molecule B (Fig-
ure 3C). In addition, residues W246 and I249 from the extra helix
(a3) of TDU2 form additional hydrophobic interactions withcreased in tumors. Paired t test (univariate) was used to compare the difference
n GC tissues from 24 patients and paired normal tissues were analyzed by
l lines in the scatter plot represent group medians. Student’s t tests were per-
s stage I, p < 0.05; **p < 0.01.
(right) based on VGLL4 expression. Survival analysis was performed using log-
DX2 (right) in GC analyzed by using paired t test.
ls of VGLL4were compared with those of YAP target genes CTGF (left), CYR61
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<60 15 22 37 59.4 1.0000
R60 18 29 47 61.7
Gender
Male 18 32 50 68.0 0.5002
Female 15 19 34 55.0
Helicobacter pylori
Positive 14 31 45 62.1 0.1201
Negative 19 20 39 51.2
Lauren
Intestinal 25 41 66 66.1 0.7860
Nonintestinal 8 10 18 55.6
Differentiation
Low 21 29 50 58.0 0.6502
Moderate or
high
12 22 34 64.7
Lymphatic invasion
Ly0-1 14 10 24 45.4 0.0287a




11 6 17 35.3 0.0251a
pT3 (>5 cm) +
pT4
22 45 67 67.2
Lymph node metastasis
N0 + N1 19 15 34 44.1 0.0130a
N2 + N3 14 36 50 72.0
Distant metastasis
M0 29 45 74 60.1 1.0000




18 15 33 45.4 0.0247a
Stage III +
stage IV
15 36 51 70.6
Total 33 51 84
Fisher’s exact test was used to test the association between two categor-
ical variables.
aRepresents statistically significant, p < 0.05.
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VGLL4: An Anticancer Drug Candidate Targeting YAPTEAD4. Besides the two short helices, the b strand of the TDU2
forms an intermolecular b sheet with TEAD4 (Figures 3A, S3D,
and S3E). The total interface area between TDU2 and TEAD4 is
up to 1,048 A˚2, suggesting that TDU2 hasmuch stronger interac-
tion with TEAD4 when compared with TDU1.
According to the structural analysis, we designed a series of
mutations based on human VGLL4 and TEAD4 to probe and
disturb the complex interface (Figure S3F). In vitro biolayer inter-
ferometry (BLI) and pull-down assays were subsequently per-
formed to assess the importance of individual amino acids170 Cancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc.on the interface (Figures 3D and 3E). In agreement with the
structural analysis, we found that the overall contribution of
TDU2 ismuch larger than that of TDU1 during complex formation
with TEAD4. Specifically, mutations of V209A, H212A, F213A,
R215A, L217A, and H212A/F213A targeting TDU1 did not
significantly affect VGLL4-TEAD4 interactions. However, muta-
tions of H240A and H240A/F241A targeting TDU2, or H212A/
F213A/H240A/F241A (HF4A) targeting both TDUs dramatically
decreased VGLL4-TEAD4 complex formation. Moreover, substi-
tution of the b strand of TDU2 with poly-Glycine only slightly
decreased VGLL4’s binding to TEAD4 (Figures 3D and 3E),
suggesting that this b strand is not essential but may help
for VGLL4-TEAD4 interaction. We then used H212A/F213A,
H240A/F241A, and HF4A as representative mutants for further
studies (Figure 3F) and confirmed their effects by coimmunopre-
cipitation (coIP) analysis (Figure 3G).
VGLL4 Functions through Competing with YAP for
TEAD4 Binding
Structural comparison of VGLL4-TEAD4 with YAP-TEAD4 and
VGLL1-TEAD4 suggested that VGLL4 and YAP have partially
overlapped binding sites on TEADs, thus probably acting as an
inhibitor of each other in terms of binding TEADs (see Supple-
mental Experimental Procedures and Figures S3F–S3H). To
further validate that VGLL4 functions through a direct com-
petition with YAP for TEAD4 binding, we examined whether
the mutations disrupting VGLL4-TEAD4 interaction will affect
VGLL4 function. As shown in Figure 4A, mutation H212A/
F213A in TDU1 slightly blocked the inhibitory effect of VGLL4
on YAP-induced TEAD4 reporter activity, while, strikingly, muta-
tion H240A/F241A in TDU2 almost completely abolished this
repression effect, suggesting that TDU2 with a tighter binding
to TEAD4 also possesses higher inhibitory activity toward YAP.
Similarly, cells transfected with VGLL4 mutant HF4A displayed
high TEAD4 reporter activity as did the empty vector. Consistent
with the luciferase assay, VGLL4 mutant H212A/F213A only
partially impaired its inhibitory function on YAP-induced CDX2
expression, while mutants H240A/F241A and HF4A completely
blocked VGLL4’s inhibition on YAP-induced target gene expres-
sion (Figure 4B). Moreover, VGLL4 mutant H212A/F213A
showed partially reduced inhibitory effect on YAP-induced cell
proliferation and colony formation in soft agar, while VGLL4
mutants H240A/F241A and HF4A almost completely lost the
inhibitory activity (Figures 4C and 4D), again indicating that
VGLL4’s binding to TEAD4 is required for its repressor function.
Next, we dissected the interplay between VGLL4, YAP, and
TEAD4 using purified recombinant proteins. As shown by pull-
down assay in Figure 4E, YAP readily competes with VGLL4 tan-
dem TDUs for TEAD4 binding in a dose-dependent manner. On
the other hand, VGLL4 tandem TDUs also competes with YAP
for TEAD4 binding, although higher concentration of VGLL4 is
required (Figure 4E). However, VGLL4 mutants defective in
TEAD4 binding could not compete with YAP (Figure 4F). We
then quantified the binding affinities between TEAD4 and YAP/
VGLL4 using BLI assay (Figure 4G). Consistently, the binding
affinity between TEAD4 and YAP (Kd = 2.1 nM) is higher than
that between TEAD4 and VGLL4 (Kd = 6.8 nM), suggesting that
higher concentration of VGLL4 would be required to compete
with YAP for TEADs binding.
Figure 2. VGLL4 Inhibits Gastric Tumor Cell Growth through Inhibiting YAP-Induced TEAD4 Transactivation
(A) Apoptosis rate in human gastric cancer cell line MGC-803 transfected with VGLL4.
(B–E) Cell viability (B), colony formation (C), TEAD4-relative luciferase activity (D), and YAP target genes levels (E) in MGC-803 cells after transfection with VGLL4
in the absence or presence of YAP.
(F) Cell viability in MGC-803 cells transfected with scramble or shVGLL4 in the absence or presence of YAP.
(G) Rescue assay of VGLL4 on TEAD4-relative luciferase activity in cells after treatment with shVGLL4 targeting its 50 UTR sequence.
(H) Transcriptional levels of YAP target genes in cells after VGLL4 knockdown.
(I) Schematic illustration of the domain organization for human YAP, TEAD4, and VGLL4. Amino acid numbering is according to human YAP1, TEAD4, and VGLL4.
(J–M) Cell growth (J), colony formation (K), TEAD4 luciferase activity (L), andCDX2mRNA levels (M) in MGC-803 cells after transfection with different deletions of
VGLL4 tandem TDU sequence in the absence or presence of YAP.
Data were expressed as means ± SD. ANOVA and Student’s t test were used; n = 3. #Versus vector-transfected group, p < 0.05; *versus YAP-transfected group,
p < 0.05; ***p < 0.01; ***p < 0.001. WT represents full-length wild-type VGLL4. delTDU1, delTDU2, and del tandem TDU represent VGLL4 constructs in which
TDU1, TDU2, and the whole tandem TDU region were deleted, respectively.
See also Figure S2.
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Figure 3. Crystal Structure of VGLL4-TEAD4 Complex
(A) Overall structure of the mouse VGLL4-TEAD4 complex. VGLL4 TDU1 and TDU2 are colored yellow and purple, respectively. One VGLL4 molecule interacts
with two TEAD4 molecules with TDU1 bound to TEAD4 A (green) and TDU2 bound to TEAD4 B (blue), respectively.
(B and C) Detailed interface between TEAD4 and TDU1 (B) or TDU2 (C) domains of mouse VGLL4.
(D) BLI analysis of interactions between TEAD4 and various VGLL4mutants. Colored curves are the experimental traces of BLI experiments formutations in TDU1
(left) and TDU2 (right), respectively.
(E) Pull-down analysis between TEAD4 and various VGLL4 mutants.
(F) Critical residues in TDU1 and TDU2 for TEAD4 binding.
(G) CoIP between TEAD4 and various VGLL4 mutants.
Substitution represents a VGLL4 construct in which the linker between TDU1 and TDU2 was substituted by a polyglycine linker. All amino acids are numbered
according to human VGLL4 except in (A)–(C). HF4A represents VGLL4 mutation H212A/F213A/H240A/F241A.
See also Figure S3 and Table S6.
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VGLL4: An Anticancer Drug Candidate Targeting YAPTaken together, these results clearly demonstrated that
VGLL4 and YAP compete with each other for TEADs binding,
and thus a ratio between their local concentrations may dictate
the function of TEADs as either transcriptional activator or
repressor.
TDUDomains AloneAre Sufficient for VGLL4 Function of
Inhibiting YAP
We then investigated whether the tandem TDU region alone
could be fully competent toward YAP inhibition as is the full-
length VGLL4. As shown in Figures 4H and 4I, all the fragments
including TDU1, TDU2, and tandem TDU, exerted inhibitory
effects on YAP-induced TEAD4 reporter activity, although to
different extents. Moreover, TDU2 exhibited a stronger inhibitory
activity than TDU1 when used alone, whereas TDU1 and TDU2
mutants with disabled TEAD4-binding showed impaired inhibi-
tory effects on YAP-induced TEAD4 reporter activity. Notably,
when compared with the full-length VGLL4, the tandem TDU
region alone was fully functional in terms of inhibiting YAP-172 Cancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc.induced TEAD4 reporter activity. These observations were fur-
ther confirmed on the levels of YAP-induced CDX2 expression
(Figure 4J), as well as proliferation and colony formation of
MGC-803 cells (Figures 4K and 4L). These results demonstrated
that the tandem TDU domains of VGLL4, especially TDU2, are
not only essential but also sufficient for VGLL4 in inhibiting
YAP function, corroborating the conclusion that VGLL4 functions
as a competitive inhibitor of YAP.
A Rationally Designed Peptide ‘‘Super-TDU’’ Potently
Inhibits GC Growth
Based on our findings that (1) the TDU region of VGLL4 is suffi-
cient for inhibiting YAP activity, and (2) the most important
binding sites for VGLL4 and YAP do not overlap on TEAD4, we
designed an inhibitor peptide termed ‘‘Super-TDU’’ targeting
YAP-TEADs interaction for therapeutic purpose (Figure 5A). As
shown by coIP experiment, the Super-TDU reduced endoge-
nous interaction between YAP and TEADs (Figure 5B). As
predicted, the Super-TDU inhibited cell viability and colony
Figure 4. The Tandem TDU Domains of VGLL4 Are Sufficient to Inhibit YAP Activity
(A–D) The functional consequences of mutations H212A/F213A, H240A/F241A, and HF4Awere evaluated in the context of full-length VGLL4 by TEAD4 luciferase
assay (A), CDX2 mRNA levels (B), cell viability (C), and clonogenic assay in soft agar (D).
(E) Pull-down assays to detect the effect of YAP (left) or VGLL4 (right) on the interaction between TEAD4 and VGLL4 or YAP, respectively.
(F) Competitive pull-down assay to detect the effect of VGLL4 mutants on YAPs binding to TEAD4.
(G) Binding affinities between TEAD4 and VGLL4/ YAP were determined by BLI experiment.
(H) Diagram of VGLL4 constructs used for functional evaluation.
(I–L) The individual TDU domains or the tandem TDU region of VGLL4, as well as their mutants were evaluated by TEAD4 reporter assay (I), target gene expression
(J), cell viability (K), and clonogenic assay (L).
Bar graphs represent means ± SD. ANOVA and Student’s t test were used; n = 3. #Versus vector-transfected group, p < 0.05. *Versus YAP-transfected group,
p < 0.05; **p < 0.01; ***p < 0.001. TDU1, TDU2, and tandem TDU represent individual or tandem TDUs alone, respectively.
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not MKN-45 (Figures 5C, 5D, and S4A). Moreover, the Super-
TDU downregulated expression of YAP-TEADs target genesCCTGF, CYR61, and CDX2 (Figures 5E and S4B). Further chro-
matin immunoprecipitation (ChIP) assays also showed that the
Super-TDU dose-dependently reduced the amount of CTGFancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc. 173
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To verify the specificity of the Super-TDU, we created two
Super-TDU mutants harboring mutations that disable TEADs
binding. As expected, the mutant Super-TDUs failed to interact
with TEADs and inhibit cell proliferation (Figures S4C and S4D).
Next, we carried out a preclinical study in which several
types of GC cell lines mentioned above were injected into the
armpits of BALB/cA nu/nu mice and allowed to form tumors
(Figure 5G). Once palpable tumors were detected, pairs of
mice were randomized to receive a tail vein injection of either
50 mg/kg (n = 5) or 500 mg/kg (n = 5) per day of the Super-
TDU peptide or an irrelevant control peptide (n = 10). In parallel,
mice were treated with 50 mg/kg 5-fluorouracil (5-FU), a con-
ventional drug used in GC treatment, intravenously as a
positive control (Figure 5H). Consistent with our in vitro obser-
vations, not only the sizes and weights of tumors, but also YAP
target genes were markedly decreased for the Super-TDU-
treated animals in a dose-dependent manner (Figures 5H, 5I,
and S4E–S4G).
Pharmacological Evaluation of the Super-TDU
We first determined the acute toxicity of the Super-TDU in
ICR mice. Our results in BALB/cA nu/nu mice showed that a
dosage of 50 mg/kg Super-TDU was equally effective as
50 mg/kg of 5-FU in terms of reducing tumor mass, tumor
volume, and human b2 microglobulin concentration (Figures
5H, S4E, S4G, S4H). However, the Super-TDU exerted no
obvious adverse toxic effects in ICR mice at a dosage of
1 mg/kg, while there was a significant decrease of white
cell and platelet number in the 5-FU-treated control group
(50 mg/kg). The maximum tolerance dose (MTD) of the
Super-TDU was >1 mg/kg body weight intravenously in mice
(Table S7). We then performed pharmacokinetic analysis of
the Super-TDU in ICR and C57BL/6 mice. Representative
curves of the Super-TDU concentration versus time were
shown in Figure 5J and pharmacokinetic parameters were
listed in Table S8 (see Supplemental Experimental Procedures).
Moreover, consistent with the downregulation of YAP-TEADs
target genes in the Super-TDU-treated mice (Figures 5I and
S4F), we found that a biotin-labeled Super-TDU peptide could
efficiently pull down the endogenous TEADs, again indicatingFigure 5. The Super-TDU Potently Inhibits Gastric Tumor Growth
(A) A structural model of the Super-TDU bound with TEAD4. The purple and cyan r
(HF and MF) critical for TEADs binding are highlighted.
(B) CoIP assay of interactions between TEAD4 and YAP in the presence of the Sup
were added into cell lysates. After incubation for 30 min, cell lysates were immu
(C and D) Evaluation of the Super-TDU by ATP cell viability assay (C) and clonog
(E) YAP target genes’ mRNA levels in MGC-803 cells treated with the Super-TDU
(F) ChIP assay in MGC-803 cells by YAP antibody in the presence of the Super-
(G) Flow chart of tumor formation assay in nude mice.
(H) Tumor formation assay to evaluate the effect of the Super-TDU on GC tumor
each mouse were photographed before further processing (left). Tumor volume
(I) Relative mRNA levels of YAP target genes in samples from (H).
(J) Pharmacokinetic studies of the Super-TDU in different mouse models. Conce
mice were presented. White and gray circles represent dose levels of 250 and 5
(K) Pull-down of endogenous TEADs by a biotin-labeled Super-TDU in MGC-803
Bar graphs represent means ± SD. ANOVA and Student’s t test were used; n = 3
p < 0.05; **p < 0.01.
See also Figure S4 and Tables S7–S9.
Cthat the Super-TDU exerts its antitumor activity via directly tar-
geting TEADs (Figure 5K).
Next, we introduced multiple tumor cell lines and evaluated
the efficacy of the Super-TDU in these different cellular contexts
(Figure S4I; Table S9). The Super-TDU significantly inhibited
growth of HeLa, MGC-803, HCT116, A549, and MCF-7 cells,
but only marginally inhibited growth of Jurkat and Raji cells, indi-
cating a selectivity of the Super-TDU in inhibiting tumor cell
growth. Consistent with our clinical analysis, we found that
YAP/VGLL4 ratio correlates well with susceptibility of tumor cells
toward the Super-TDU (Figures S4J and S4K). For example,
MGC-803 cells (high YAP/VGLL4 ratio) were more susceptible
to the Super-TDU than HEK293 cells (low YAP/VGLL4 ratio).
Thus the Super-TDU may specifically target tumor cells with an
elevated YAP/VGLL4 ratio.
Taken together, these results suggested that the Super-TDU
is relatively safe and specific as a drug candidate, which may
have a broader antitumor activity toward YAP-driven human
cancers.
The Super-TDU Inhibits Tumor Growth of Human
Primary GC
To further validate the clinical relevance of our findings, we
assessed the efficacy of the Super-TDU on primary gastric
tumor cells (T1 and T2), which were derived from two individual
patients. Paired normal tissue cells (N1 and N2), as well as
MGC-803 cells, were used as controls. We found that the cells
with a higher ratio of YAP to VGLL4 (sample T1) exhibited an
obvious impairment in cell growth and colony formation upon
treatment with the Super-TDU, while only a marginal influence
was observed for the cells with lower ratio of YAP to VGLL4
(sample T2) (Figures 6A, 6B, S5A, and S5B). By contrast, 5-FU
inhibited almost equally the growth and colony formation of
all the cells tested (Figures 6B, S5C, and S5D). These obser-
vations were further confirmed by tumor formation assay and
expression of YAP-TEADs target genes in nude mice (Figures
6C–6E). Taken together, these results indicated a promising
therapeutic potential of the Super-TDU in treating GC by directly
targeting YAP-TEADs, and importantly, unlike the conventional
drug compound 5-FU, its antitumor activity tends to be specific
toward tumors with an elevated ratio of YAP to VGLL4.egions are derived from VGLL4 and YAP, respectively. Two clusters of residues
er-TDU. MGC-803 cells were lysed, and then different doses of the Super-TDU
noprecipitated with YAP antibody and analyzed by western blotting.
enic assay (D) in MGC-803 cells.
.
TDU.
progression. Mice were photographed after sacrifice. Tumors harvested from
for each group (eight mice) was plotted (right).
ntration versus time curves of the Super-TDU in C57BL/6 (left) and ICR (right)
00 mg/kg, respectively. Results were expressed as means ± SD.
cells.
. #Versus vector-transfected group, p < 0.05. *Versus YAP-transfected group,
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H. pylori-Infected Mouse Model
H. pylori infection is worldwide and once acquired it becomes
chronic and probably persists for life if untreated. Multiple
lines of evidence demonstrate that H. pylori together with
cocarcinogens, such as N-methyl-N0-nitro-N-nitrosoguanidine
(MNNG), induce gastric carcinogenesis in animals (Danon
and Eaton, 1998; Han et al., 2002). Furthermore, previous
studies have shown that YAP mRNA levels were increased in
mouse mucosa after H. pylori infection (Takaishi and Wang,
2007).
To corroborate our observations of the Super-TDU in treating
nude mice, we assessed its therapeutic effect in H. pylori-
infected GC mouse model. Here, we attempted to develop GC
mousemodels through the administration ofH. pylori intragastri-
cally with alkylating agent MNNG in drinking water (Figure 6F).
C57BL/6 mice were orally gavaged 50 ml of bacterial suspension
(13 106 CFU) every day. MNNG (100 mg/ml) was added to the
drinking water for a period up to 2 months. After treatment with
MNNG, mice were randomized to receive 500 mg/kg per day of
the super-TDU (control peptide as negative control, 5-FU as
positive control), which persisted for at least 4 months before
sacrifice. Consistent with a previous report (Takaishi and
Wang, 2007), we found that YAP expression was significantly
elevated in H. pylori-infected mice (Figure 6G). Tumor numbers
in the Super-TDU-treated group displayed a significant de-
crease, compared with those in the control group, indicating
an obvious therapeutic effect of the Super-TDU on gastric carci-
nogenesis (Figure 6H). These observations were further con-
firmed by Ki67 IHC staining (Figure 6I). Consistently, we found
that expressions of YAP-TEADs target genes (CTGF, CYR61,
and CDX2) were downregulated in mice treated with the
Super-TDU (Figure 6J). Taken together, these results confirmed
our evaluation of the Super-TDU in nude mice, further demon-
strating therapeutic potentials of the Super-TDU in treating
human cancer with YAP-activation.
DISCUSSION
The Hippo pathway controls multiple cellular processes related
to cell proliferation and apoptosis and its dysregulation has
been linked to various cancers (Chan et al., 2011; Harvey and
Tapon, 2007; Pan, 2010; Steinhardt et al., 2008; Zhao et al.,
2010). As a tumor suppressor pathway, therapeutic targeting
of the Hippo signaling has recently surfaced (Stanger, 2012;Figure 6. The Super-TDU Inhibits Human Primary GC Growth and GC
(A and B) Evaluation of the Super-TDU by cell viability (A) and colony formation
represented as means + SD.
(C and D) Evaluation of the Super-TDU by tumor formation of primary gastric ca
(E) Relative mRNA levels of YAP target genes in samples from (C) and (D).
(F) Flow chart of treating H. pylori-induced GCmice with the Super-TDU. Four-we
fed sterilized commercial pellet diets and given sterile water ad libitum. A total o
(G) YAP mRNA levels in H. pylori-infected GC mice.
(H) Pictures of stomach mucosa show gross gastric tumors (left). Arrows indicat
(I) Ki-67 staining of adenomas from H. pylori-infected GC mice.
(J) Relative mRNA levels of YAP target genes in gastric tissue of H. pylori-infecte
Bar graphs represent means ± SD. ANOVA and Student’s t test were used. *Versu
primary gastric cancer cells; N1 and N2 represent paired control cells.
See also Figure S5.
CSudol et al., 2012). Our current work identified the clinical
relevance of VGLL4 as a YAP antagonist and found its TDU
region is sufficient for inhibiting YAP activity. These findings led
to the generation of a peptide-based YAP inhibitor, which ex-
hibits potent antitumor activity against gastric cancer in vitro
and in mice.
From a clinical point of view, both YAP and VGLL4 levels
should be well confined within a suitable range and thus
maintain a concentration balance or ratio to properly control
Hippo signaling intensity required for normal development
and homeostasis, which, however, may be disrupted under
certain disease conditions such as cancers. Consistent with
this notion, we found that YAP/VGLL4 ratios in clinical samples
were sharply skewed and well correlated with tumor progres-
sion in GC. Moreover, we observed an inhibitory effect on a
range of different cancer cell lines treated with the Super-
TDU, but found that tumor cells with a relatively high YAP/
VGLL4 ratio were more susceptible to such treatment. These
observations were further confirmed by our clinical study of
VGLL4 and therapeutic evaluation of the Super-TDU in colo-
rectal carcinoma (data not shown). Thus the Super-TDU
appears to have a broad but specific antitumor activity toward
YAP-driven human cancers in which YAP/VGLL4 ratio should
be considered as an important prognostic marker for personal-
ized treatment.
The observations that YAP levels, especially in the nucleus,
increase specifically under pathological conditions makes it an
ideal drug target. Although it has been increasingly revealed
that selective inhibition of YAP-induced TEADs transactivation
is ‘‘a promising and pharmacologically viable strategy’’ with min-
imal side effects in treating cancers related to YAP overexpres-
sion (Cai et al., 2010; Koontz et al., 2013; Liu-Chittenden et al.,
2012), studies regardingYAP inhibitors for therapeutic purposes
are still very limited. VGLL4 functions as a physical antagonist of
YAP and blocks YAP oncogenic activity at transcriptional level,
hence providing a more effective and direct way to correct the
consequences caused by excessive YAP.
Our results clearly demonstrated that both VGLL4 and YAP
levels were altered in GC samples. Currently, however, the
molecular mechanism by which the expressions of YAP and
VGLL4 are regulated in cancer remains unknown. There could
be multiple pathological reasons accounting for the disruption
of YAP-VGLL4 balance. Compared with other pathways corre-
lated with tumorigenesis, DNA mutations are rare in Hippo
pathway, while epigenetic silencing of some tumor suppressorTumorigenesis in the H. pylori-Infected Mouse Model
(B) assays in primary gastric cancer cells derived from GC patients. Data are
ncer cells T1 (C) and T2 (D) in nude mice.
ek-old specific-pathogen-free (SPF) C57BL/6-slac mice were used. They were
f 80 mice were reared, including 20 normal controls.
e adenomas. Average tumor numbers were calculated (right).
d GC mice.
s control-treated group, p < 0.05. NS, no significance. T1 and T2 represent two
ancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc. 177
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cancer (Chan et al., 2011, Chen et al., 2012; Zeng and Hong,
2008; Zhou et al., 2009). It is also possible that VGLL4 loss in
cancer could be related to epigenetic changes. Recently, it
was reported that aberrant Wnt signaling causes YAP upregula-
tion in liver cancer (Wang et al., 2013). In addition, several other
tumorigenesis-related pathways have been reported to cross-
talk with Hippo pathway (Azzolin et al., 2012; Barry et al., 2013;
Fernandez et al., 2009; Konsavage et al., 2012; Varelas et al.,
2010). Hence, it is also possible that aberration of these path-
ways may lead to dysregulation of VGLL4 and YAP in cancer.
On the other hand, both negative (Genevet et al., 2010; Hamar-
atoglu et al., 2006; Neto-Silva et al., 2010) and positive (Jukam
et al., 2013) feedback regulation of YAP has been documented,
indicating tissue-dependent plasticity and intrinsic complexity of
the YAP-related signaling network. Notably, dysregulation of
signaling pathways induced by H. pylori infection is attributed
to 80% of GC cases (Houghton and Wang, 2005). How such
infection may cause malfunction of Hippo pathway in GC re-
mains to be determined. In the future, mechanistic elucidation
of VGLL4 and YAP dysregulations in cancer will not only further
our understanding of tumorigenesis, but may also help to find
new biomarkers and facilitate patient selection.EXPERIMENTAL PROCEDURES
Collection of Human Gastric Cancer Specimens
All samples used in this research were collected with written informed consent
from patients. The use of human tissues was approved by the Institutional
Ethics Board of the Shanghai Institutes for Biological Sciences (SIBS) and
conforms to the Helsinki Declaration and to local legislation. All patients
receiving treatment on this study were treated as part of a clinical protocol.
See the Supplemental Experimental Procedures for details.
Tissue Microarray and Immunohistochemical Staining
Gastric cancer and normal tissue microarray sections were prepared by
Shanghai Outdo Biotech. This tissue array contains tissues from 31 cases of
dysplasia, 91 cases of gastric tumors, and paired normal tissue. The follow-
up time of GC patients ranged from 2 to 66 months. This array was used
for IHC staining analysis. For details, see the Supplemental Experimental
Procedures.
Cell Viability Assay
Cells were transfected with the indicated plasmids of pcDNA3.1 or Flag-
VGLL4 wild-type or mutant and/or HA-tagged YAP. ATP cell viability assay
was used for detecting cell proliferation. ATP content was measured in accor-
dance with the protocol of the CellTiter-Glo luminescent cell viability assay kit
(Promega). Briefly, 100 ml of assay reagent was added to the wells and mixed
for 2 min at room temperature. After 10 min, intracellular ATP content was
measured using a luminescence multilabel counter (Envision, Perkin Elmer).
Cell viability was calculated using the following equation:
% Cell viability= ½valueðtestÞ  valueðblankÞ=½valueðcontrolÞ
 valueðblankÞ3100:
Protein Purification and Structure Determination
Proteins used in this study were expressed in Escherichia coli using pET28a-
derived vectors and purified by affinity chromatography and size-exclusive
chromatography. Diffraction data were collected at beamline BL17U,
Shanghai Synchrotron Radiation Facility (SSRF) of China. See the Supple-
mental Experimental Procedures for details.178 Cancer Cell 25, 166–180, February 10, 2014 ª2014 Elsevier Inc.Design and Production of the Super-TDU
The basic rationale for the Super-TDU design lies in that the tandem TDU
region of VGLL4 is fully competent in terms of competing with YAP for
TEAD binding and therefore inhibiting YAP-mediated TEAD transacti-
vation, and VGLL4 and YAP have overlapped but distinct primary binding
sites on TEAD. The amino acid sequence of the Super-TDU contains
‘‘SVDDHFAKSLGDTWLQIGGSGNPKTANVPQTVPMRLRKLPDSFFKPPE.’’
The Super-TDU was expressed and purified in E. coli. For details, see the
Supplemental Experimental Procedures. In addition, two Super-TDU mutants
were constructed by substitution of underlined residues MF or HFMF with
alanines (termed as mutations MF2A and HFMF4A, respectively).Animal Experiments
Male nude mice (BALB/cA-nu/nu) and C57/BL6 were obtained from Shanghai
Experimental Animal Center and maintained in pathogen-free conditions. For
animal research, all procedures for animal experimentation were performed
in accordance with the Institutional Animal Care and Use Committee guide-
lines of the Animal Core Facility of the Institutes of Biochemistry and Cell
Biology (SIBCB). The approval ID for using the animals was 081 by the Animal
Core Facility of SIBCB.
During the tumor formation assay of BALB/c-nu/nu, cancer cell lines were
injected at the flank of the mice (1 3 106 to 2 3 106). Tumor volumes were
then measured. Once tumors were detected, mice were injected once daily
with Super-TDU in saline at the 0.1 ml injection volume via the tail vein.
Mice were randomized to receive either 50 mg/kg or 500 mg/kg per day of
super-TDU peptide or control peptide. In addition, mice were treated with
50 mg/kg 5-fluorouracil (5-FU) intravenously as a positive control.
For theH. pylori-infectedmice model, SPF C57BL/6-slac mice were housed
in an air-conditioned biohazard room designed for infectious animals, with a
12 hr light/dark cycle. The mice were inoculated with H. pylori SS1 grown on
solid medium and harvested by swabbing, a single intragastric dose of a
1 3 107 CFU/ml. Normal mice (n = 20) were given same amount of normal
saline and were housed in isolators in order to prevent risk of infection.
See the Supplemental Experimental Procedures for details.Statistical Analysis
Statistical analysis was performed using the SAS statistical software package
(9.1.3). Data are presented as means ± SD. ANOVA and Student’s t test were
used for continuous variables. Fisher’s exact test was used for categorical
variables. Survival analysis was performed using log-rank test. The Cox pro-
portional hazards model was used for multivariate analysis, and calculation
of the hazard ratios and confidence intervals was performed with the
ascending step-by-step maximum likelihood method. A p value < 0.05 was
considered significantly different.
Other methods are described in the Supplemental Experimental
Procedures.ACCESSION NUMBERS
The Protein Data Bank accession number for the crystal structure of VGLL4-
TEAD4 complex reported in this paper is 4LN0.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and nine tables and can be found with this article online at
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